Overview

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
Phase:
Phase 1
Details
Lead Sponsor:
Polaris Group
Treatments:
Sorafenib